SG&A Efficiency Analysis: Comparing Bristol-Myers Squibb Company and Wave Life Sciences Ltd.

SG&A Efficiency: Bristol-Myers vs. Wave Life Sciences

__timestampBristol-Myers Squibb CompanyWave Life Sciences Ltd.
Wednesday, January 1, 201456990000002999000
Thursday, January 1, 2015500100000010393000
Friday, January 1, 2016500200000015994000
Sunday, January 1, 2017484900000026975000
Monday, January 1, 2018455100000039509000
Tuesday, January 1, 2019487100000048869000
Wednesday, January 1, 2020766100000042510000
Friday, January 1, 2021769000000046105000
Saturday, January 1, 2022781400000050513000
Sunday, January 1, 2023777200000051292000
Monday, January 1, 20248414000000
Loading chart...

Igniting the spark of knowledge

SG&A Efficiency: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Bristol-Myers Squibb Company, a giant in the sector, has consistently managed its SG&A expenses, averaging around $6 billion annually from 2014 to 2023. Notably, their expenses peaked in 2022, reflecting strategic investments. In contrast, Wave Life Sciences Ltd., a smaller player, has seen a steady increase in SG&A expenses, growing by over 1,600% from 2014 to 2023. This growth highlights their aggressive expansion strategy. While Bristol-Myers Squibb's expenses are significantly higher, the efficiency of their spending is evident in their market dominance. Wave Life Sciences, with its leaner budget, focuses on innovation and niche markets. This comparison underscores the diverse strategies companies employ to balance growth and operational efficiency.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025